Alar Cartilages Hypoplasia-Coloboma-Telecanthus Syndrome

Alar cartilages hypoplasia–coloboma–telecanthus syndrome is a descriptive label for a birth-difference (a congenital condition) where:

• the alar cartilages of the nose (the small curved supports that shape each nostril) are under-developed (hypoplastic),

• there is an eyelid coloboma (a notch or gap in the eyelid present from birth), and

• there is telecanthus (the inner corners of the eyelids sit wider apart than usual, even if the pupils are not far apart).

This triad was reported decades ago in two sisters and has very sparse literature since then. Because so few cases exist, doctors today usually place patients with this facial pattern within the frontonasal dysplasia / FREM1-related spectrum—conditions that can produce eyelid colobomas, a wide or notched/bifid nasal tip with alar hypoplasia, and increased inner eye corner distance. One especially relevant diagnosis is Manitoba oculotrichoanal (MOTA) syndrome, a FREM1-related disorder that often includes eyelid colobomas, telecanthus/hypertelorism, and nasal alar changes. In practice, evaluation and care for this triad largely follow what we know from eyelid coloboma management, frontonasal dysplasia, and FREM1-related disorders. BioMed Central+3Genetic Diseases Center+3MedlinePlus+3

This is an extremely rare birth condition that affects the shape of the middle face, especially the nose and the area between the inner corners of the eyes. The alar cartilages are the small, wing-like supports at each side of the tip of the nose. In this condition, these cartilages are under-developed (hypoplasia) and may have a split or notch (coloboma). The eyes also look farther apart at the inner corners—a feature called telecanthus. The condition was first described in two sisters and, to the best of current medical records, no similar new cases have been reported since 1976. Because it is so rare, doctors learn about it mainly from those first reports and from rare-disease catalogs. Orpha+1

Scientists list it as a very rare dysmorphic disorder (meaning a pattern of congenital differences in body shape and structure). Some sources list autosomal-recessive inheritance as plausible because it occurred in siblings, but the exact gene cause is unknown. Orpha+1

---

Other names you might see

• Alar cartilages hypoplasia–coloboma–telecanthus syndrome (preferred name in rare-disease catalogs)

• ORPHA:2007 (Orphanet code)

• MONDO:0008744 (Monarch Disease Ontology code)

• MedGen CUI C4302677 (NCBI/MedGen)
  All these names and codes refer to the same extremely rare condition described above. Orpha+2monarchinitiative.org+2

---

Types

There are no official subtypes because so few patients have been recorded. In practice, clinicians might group patients in ways that help with assessment and planning care:

1. Isolated vs. associated form
   Isolated: only the nose/eye features are present.
   Associated: other facial features are present (e.g., wide nasal bridge, convex nasal ridge, non-midline cleft of upper lip). These associated features have been listed among reported phenotypes in rare-disease summaries. MalaCards

2. Unilateral vs. bilateral nasal involvement
   Unilateral: one side of the alar cartilage is more affected.
   Bilateral: both sides are similarly under-developed or cleft.

3. Mild, moderate, severe
   Mild: subtle alar thinning and slight telecanthus.
   Moderate: clear alar notching/coloboma and noticeable telecanthus.
   Severe: large alar defects, clefting of the ala nasi, and marked telecanthus—features that overlap with the phenotype list from catalog summaries. MalaCards

These “types” are pragmatic, not official. They help clinicians describe what they see and plan treatment in the absence of formal subclassification.

---

Causes

Because only two patients have been documented, the exact cause is unknown. The items below explain likely or possible contributors based on how the face normally forms in the embryo and on what is known about similar craniofacial conditions. Where evidence is general rather than syndrome-specific, we say so.

1. Autosomal-recessive inheritance (suspected) — The two siblings in the only report suggest a recessive pattern, though no gene has been identified. Orpha+1

2. Early disturbance of the frontonasal prominence — The nose and midface arise from this embryonic area; disruption can under-develop the alar cartilages (general craniofacial biology, not syndrome-specific).

3. Abnormal fusion of nasal processes — If the lateral and medial nasal processes do not join normally, notches (colobomas) of the nasal ala can result (general principle).

4. Abnormal development of the medial canthal region — Telecanthus reflects increased distance between inner eyelid corners; it can follow altered growth or position of the canthal tendons (general principle; telecanthus definition). MalaCards

5. Variants in unknown craniofacial genes — Many genes control cartilage, bone, and eyelid position; a yet-unknown variant could underlie this condition (inference due to lack of identified gene). MalaCards

6. Modifier genes — Even with the same primary variant, modifier genes can change severity of alar hypoplasia or telecanthus (general genetics concept).

7. Consanguinity (possible risk factor) — When parents are closely related, recessive conditions are more likely; this is a general risk, not reported specifically for this syndrome.

8. Neural crest cell migration disturbance — These cells build much of the face; migration errors can cause midface differences (general craniofacial science).

9. Cartilage patterning errors — The alar cartilages must curve and thicken correctly; patterning faults can leave thin or split rims (general principle).

10. Extracellular matrix defects — Weak matrix can impair cartilage strength and shape (general principle).

11. Maternal vitamin A (retinoid) exposure — Excess retinoids are known teratogens for craniofacial structures (general teratology; not documented for this exact syndrome).

12. Maternal diabetes — Associated with increased risk of craniofacial differences in general (not specific to this syndrome).

13. First-trimester infections — Certain infections can disturb facial development broadly (general teratology).

14. Placental insufficiency — Reduced early blood flow may impair growth of delicate facial elements (inference).

15. Mechanical factors in utero — Prolonged pressure can affect nose shape in some cases, though this rarely explains cartilage coloboma (general obstetric principle).

16. Epigenetic influences — Changes in gene regulation (not sequence) can alter craniofacial development (general concept).

17. Environmental toxins — Some chemicals disrupt neural crest development (general teratology data).

18. Nutritional deficiencies (e.g., folate) — Low folate increases some craniofacial risks in general; relevance here is speculative.

19. Vascular disruption sequences — A temporary loss of blood supply in the embryo can cause localized defects (general mechanism).

20. Stochastic (chance) developmental variation — Rare, non-heritable events can produce unique patterns in a single family.

Important: Only items #1 and “unknown cause” are specifically grounded in the rare-disease listings for this syndrome; the rest describe general mechanisms that plausibly affect the same facial structures.

---

Symptoms and signs

From case summaries and phenotype catalogs, plus logical effects of the anatomic differences:

1. Telecanthus — The inner corners of the eyelids are set wider apart than usual; pupils may be normally spaced. MalaCards

2. Under-developed nasal alae — The outer wings of the nose look thin or small. MalaCards

3. Coloboma (notch) of the alar cartilage — A split or gap at the rim of the nostril (ala). MalaCards

4. Cleft ala nasi — A deeper cleft through the ala on one or both sides. MalaCards

5. Wide nasal bridge — The top of the nose appears broad. MalaCards

6. Convex nasal ridge — The nasal profile may bulge outward. MalaCards

7. Hypertelorism (sometimes) — Overall eye sockets may be wider apart in some descriptions. MalaCards

8. Non-midline cleft of the upper lip (reported) — A small cleft not exactly at the center. MalaCards

9. Cosmetic concern and psychosocial stress — Differences in facial symmetry can affect self-image and social comfort (general effect).

10. Nasal airflow problems — A notched or weak ala can collapse inward during breathing, causing noisy breathing or mouth breathing (mechanical effect of alar weakness).

11. Dryness or crusting at the nostril rim — Irregular edges can irritate skin and mucosa (practical observation).

12. Snoring or sleep-disordered breathing — If airflow is limited, snoring or mild obstructive symptoms can occur (general respiratory principle).

13. Feeding difficulties in infancy — Facial clefts or weak nasal rims can complicate suck and breathing coordination (general craniofacial care).

14. Speech resonance differences — Nasal airflow changes may alter voice quality (hypernasality or hyponasality) (general ENT concept).

15. Eye discomfort from wind/tearing — Telecanthus can change eyelid fit, sometimes leading to tearing or irritation (general ophthalmic effect).

Phenotype items 2–8 align with the curated list of features in rare-disease databases. MalaCards

---

Diagnostic tests

A) Physical examination

1. Craniofacial inspection — A specialist looks at nose shape, nostril rims, and eyelids to spot alar hypoplasia, alar notches, and telecanthus. Catalog definitions guide recognition. Orpha

2. Anthropometric measurements — Measuring inner canthal distance, interpupillary distance, and outer canthal distance helps confirm telecanthus (inner canthi far apart, pupils normal). MalaCards

3. Nasal valve assessment — Gentle observation during quiet and deep breathing to see if the alar rim collapses inward.

4. Oral and lip exam — Checks for a non-midline cleft of the upper lip and dental arch alignment, which are listed phenotypes. MalaCards

5. General dysmorphology exam — Looks for other midface signs (wide nasal bridge, convex ridge, hypertelorism) that appear in phenotype summaries. MalaCards

B) Manual tests and bedside procedures

6. Cottle maneuver — The clinician gently pulls the cheek sideways; easier breathing suggests collapse at the nasal valve due to weak alar support (simple office test).

7. Taping trial of the ala — Temporary skin tape supports the alar rim; improvement in airflow or snoring suggests the rim itself needs support (a practical pre-surgical test).

8. Nasal speculum and endoscopy (rigid or flexible) — Directly sees the inside of the nostril to judge the extent and depth of the alar notch or cleft.

9. Standardized facial photography — Frontal/profile images with scale bars for documenting distances and planning surgery; also useful for follow-up.

10. 3D surface scanning / photogrammetry — Non-invasive mapping of nasal and canthal landmarks to quantify shape differences precisely (widely used in craniofacial clinics).

C) Laboratory and pathological / genetic tests

11. Genetic counseling session — Reviews family history; because a recessive pattern is suspected, counseling helps parents understand recurrence risk. MalaCards

12. Chromosomal microarray — Screens for large deletions/duplications; while no specific change is known for this syndrome, it helps rule out other syndromes with telecanthus.

13. Craniofacial gene panel or exome sequencing — No gene is established, but sequencing can find variants in known craniofacial genes and exclude mimicking conditions (inference due to “no known gene”). MalaCards

14. Basic lab work when planning surgery — Routine pre-operative tests (CBC, coagulation) if reconstruction is considered (general surgical practice).

15. Pathology of resected tissue (rarely needed) — If tissue is removed during reconstruction, pathology confirms cartilage quality and rules out unexpected lesions (procedural standard).

D) Electrodiagnostic and physiologic tests

16. Active anterior rhinomanometry — Measures nasal airflow and resistance with pressure sensors during breathing; helps quantify how much the weak alar rim limits airflow.

17. Overnight polysomnography (sleep study) — If snoring or pauses in breathing are reported, a sleep study checks for obstructive sleep apnea due to nasal valve weakness (uses multiple physiologic sensors).

E) Imaging tests

18. Low-dose facial bone CT (with 3D reconstruction) — Shows the bony nasal bridge, pyriform aperture, and soft-tissue thickness; assists surgical planning and distinguishes telecanthus from bony hypertelorism.

19. High-resolution nasal MRI (selected cases) — Defines soft tissues, cartilage, and scarring without radiation; helpful when cartilage quality must be mapped for reconstruction.

20. Ophthalmologic evaluation (slit-lamp + external photos; add orbital imaging only if needed) — Confirms telecanthus versus hypertelorism and looks for any eyelid tendon issues; telecanthus is defined clinically but imaging may be added in complex cases. MalaCards

Non-pharmacological treatments (therapies & others)

(Each item includes Description → Purpose → Mechanism)

1. Frequent eye lubrication (non-medicated tears/gel at daytime, ointment at night).
   Protects the cornea when the eyelid gap leaves it exposed → reduces dryness and micro-abrasions → forms a temporary tear-film barrier that lowers friction and evaporation. NCBI

2. Moisture chamber/eye shield at sleep.
   Retains humidity and blocks air drafts → improves overnight corneal hydration → creates a localized humid micro-environment.

3. Eyelid taping (short-term, gentle).
   Temporarily narrows the gap → protects the cornea during naps or wind exposure → decreases exposure time.

4. Prescription protective eyewear (wrap-around).
   Shields from wind/particles/UV → prevents corneal irritation → mechanical barrier.

5. Amblyopia prevention program (if one eye sees better).
   Early vision therapy/patching schedule → keeps both eyes developing → leverages brain plasticity in childhood to prevent “lazy eye.” NCBI

6. Lid hygiene & warm compress routine.
   Clears oil glands, stabilizes tear film → fewer surface symptoms → heat liquefies meibum; hygiene reduces biofilm.

7. Scleral or large-diameter bandage contact lens (specialist-fit).
   Creates a fluid reservoir over the cornea → continuous lubrication and protection → vaults the cornea under a saline bath.

8. Temporary Botulinum-induced ptosis (specialist-only).
   Medical droop partly closes the eye → short-term surface protection before repair → weakens levator to lower exposure (procedure, not home therapy).

9. Silicone scar sheets post-repair.
   Flattens and softens scars → better eyelid/nasal contour → modulates collagen remodeling.

10. Speech/voice therapy (if nasal airflow affects resonance).
    Optimizes articulation and resonance → improves intelligibility → targeted exercises for velopharyngeal control.

11. Feeding support in infants (positioning, pacing).
    Helps breathing–feeding coordination → safer feeds → reduces nasal regurgitation and aspiration.

12. Sun/UV precautions (hat, shade, SPF around scars).
    Prevents hyperpigmented scars and irritation → better cosmetic outcome → limits UV-driven melanocyte activation.

13. Psychosocial support and counseling.
    Builds coping skills and self-esteem → buffers social stress → evidence-based cognitive/behavioral strategies.

14. Family genetic counseling.
    Explains inheritance/testing options → informed future planning → clarifies autosomal-recessive risks in FREM1-related forms. MedlinePlus

15. Early-intervention developmental services (as needed).
    Monitors vision-linked learning → supports school readiness → structured visual accommodations.

16. Protective activity planning.
    Avoid dry/windy/dusty environments during healing → fewer corneal events → practical trigger control.

17. Humidifier at home.
    Adds ambient moisture → supports tear film → reduces evaporative loss.

18. Nasal stents/splints after reconstruction (surgeon-directed).
    Maintains nostril shape → prevents collapse while healing → mechanical scaffolding.

19. Positioning during sleep (side-lying away from exposed eye).
    Reduces nighttime exposure → protects epithelium → simple behavioral change.

20. Regular multidisciplinary follow-up (ophthalmology, craniofacial, ENT, plastics).
    Early detection of issues → timely intervention → team-based, guideline-style care. NCBI

---

Drug treatments

Important note: there is no medicine that “cures” the congenital anatomy. Medicines here protect the eye, treat surface inflammation or infection, manage pain/allergy, and support surgical care. Doses are typical ranges for general orientation—final choices are made by the treating clinician.

1. Carboxymethylcellulose/artificial tears (drops/gel).
   Class: Ocular lubricant. Dose/time: 1 drop q2–4h PRN (gel nightly). Purpose: Relieve dryness. Mechanism: Increases tear viscosity/retention. Side effects: Temporary blur/rare irritation. NCBI

2. Lubricating ophthalmic ointment (e.g., petrolatum/mineral oil).
   Class: Ocular lubricant. Use: Bedtime and naps. Purpose: Night protection. Mechanism: Occlusive film against evaporation. Side effects: Blur after application.

3. Topical antibiotic ointment (e.g., erythromycin) for corneal epithelial defects.
   Class: Macrolide antibiotic. Use: 2–4×/day short course. Purpose: Prevent bacterial keratitis. Mechanism: Inhibits bacterial protein synthesis. Side effects: Mild irritation; rare allergy. NCBI

4. Fluoroquinolone eye drops (e.g., moxifloxacin) if corneal ulcer is suspected.
   Class: Broad-spectrum antibiotic. Use: Intensive dosing per protocol. Purpose: Treat infection. Mechanism: DNA gyrase/topoisomerase inhibition. Side effects: Stinging; resistance stewardship needed. NCBI

5. Short course topical corticosteroid (e.g., loteprednol) when surgeon indicates.
   Class: Anti-inflammatory. Use: Tapered dosing post-op or for surface inflammation. Purpose: Reduce inflammation/scar. Mechanism: Dampens cytokine signaling. Side effects: IOP rise, cataract risk with prolonged use—specialist monitoring.

6. Topical cyclosporine 0.05–0.1% (chronic surface inflammation/dry eye).
   Class: Calcineurin inhibitor. Use: 1 drop bid; benefits after weeks. Purpose: Improve tear quality/inflammation. Mechanism: T-cell modulation of lacrimal/ocular surface. Side effects: Burning on instillation.

7. Lifitegrast 5% (alternative to cyclosporine).
   Class: LFA-1 antagonist. Use: 1 drop bid. Purpose: Dry-eye inflammation control. Mechanism: Blocks LFA-1/ICAM-1 interaction. Side effects: Dysgeusia, irritation.

8. Topical antihistamine/mast-cell stabilizer (olopatadine/ketotifen) for itch/allergy.
   Class: Antiallergic. Use: 1 drop bid. Purpose: Reduce rubbing/irritation. Mechanism: H1 blockade plus mast-cell stabilization. Side effects: Mild stinging.

9. Cycloplegic drops (e.g., cyclopentolate) during acute corneal injury pain.
   Class: Antimuscarinic. Use: Short course. Purpose: ciliary spasm relief. Mechanism: Paralyzes accommodation; reduces pain. Side effects: Light sensitivity, rare systemic effects in kids.

10. Hypertonic saline 5% drops/ointment for recurrent corneal edema after exposure episodes.
    Class: Decongestant salt. Use: Drops day, ointment night. Purpose: Draw fluid from cornea. Mechanism: Osmotic gradient. Side effects: Stinging.

11. Oral analgesics (acetaminophen/ibuprofen) peri-injury or post-op.
    Class: Analgesic/NSAID. Use: Weight-based dosing. Purpose: Pain control. Mechanism: COX inhibition (NSAIDs); central analgesia (acetaminophen). Side effects: GI upset (NSAIDs), liver risk (acetaminophen overdose).

12. Topical antibiotic–steroid combination (short, surgeon-directed) after eyelid surgery.
    Purpose: Reduce infection and inflammation. Caution: Short, monitored use only.

13. Nasal saline sprays/gel after nasal work or when alar rims are fragile.
    Class: Isotonic saline. Use: Several times/day. Purpose: Humidify mucosa. Mechanism: Moistens and clears crusts. Side effects: Minimal.

14. Topical nasal mupirocin for localized vestibule skin infection (physician-directed).
    Class: Antibiotic. Use: 2–3×/day for 5–7 days. Purpose: Treat staph colonization/infection. Side effects: Local irritation.

15. Antiemetics (ondansetron) in peri-operative pediatric care.
    Class: 5-HT3 antagonist. Purpose: Reduce vomiting that could strain fresh repairs. Side effects: Headache, constipation.

16. Antibiotic prophylaxis (surgeon protocol) for complex craniofacial procedures.
    Class: Beta-lactams or alternative. Purpose: Prevent surgical-site infection. Side effects: Allergy, GI upset.

17. Short-course oral antibiotics when clear bacterial preseptal cellulitis or skin infection occurs.
    Choice: According to local patterns/pediatric guidance.

18. Vitamin A ophthalmic ointment (where available) to support epithelial healing.
    Mechanism: Supports differentiation of ocular surface epithelium.

19. Antiglaucoma drops only if steroid-induced IOP rise occurs (rare, specialist-monitored).
    Class: Beta-blocker/prostaglandin analog, etc. Purpose: IOP control. Caution: Pediatric use is specialist territory.

20. Sedation/general anesthesia agents (not take-home “drugs,” but essential) for safe, precise pediatric eyelid/nasal reconstruction.
    Purpose: Pain-free, motion-free surgery with stable airway.

(Clinical reasoning for eye-surface care and eyelid coloboma management is grounded in ophthalmology references.) NCBI

---

Dietary “molecular” supplements

These do not correct the anatomy; they support healing/eye surface health. Discuss with the clinician to avoid interactions.

1. Omega-3 fatty acids (EPA/DHA 1–2 g/day in older children/adults; pediatric per weight).
   Function: Improves meibomian gland oil quality → better tear film. Mechanism: Anti-inflammatory lipid mediators.

2. Vitamin A (within RDA; avoid excess).
   Function: Supports surface epithelium. Mechanism: Gene regulation in epithelial differentiation.

3. Vitamin C (250–500 mg/day age-appropriate).
   Function: Collagen synthesis for wound repair. Mechanism: Cofactor for prolyl/lysyl hydroxylases.

4. Zinc (within RDA).
   Function: Protein synthesis and immunity. Mechanism: Enzyme cofactor in healing pathways.

5. Copper (trace, within RDA).
   Function: Cross-linking of collagen/elastin. Mechanism: Lysyl oxidase cofactor.

6. Vitamin D (supplement to achieve sufficiency).
   Function: Immune modulation and bone/facial growth support. Mechanism: Nuclear receptor signaling.

7. L-proline/glycine (via adequate protein intake).
   Function: Collagen building blocks. Mechanism: Substrate for extracellular matrix.

8. N-acetylcysteine (low dose, clinician-guided).
   Function: Mucolytic/antioxidant; may reduce sticky mucus on ocular surface. Mechanism: Breaks disulfide bonds; glutathione precursor.

9. B-complex (within RDA).
   Function: Energy metabolism in healing tissues. Mechanism: Cofactors in cellular respiration.

10. Selenium (within RDA).
    Function: Antioxidant enzyme support (GPx). Mechanism: Redox balance during healing.

---

Regenerative / stem-cell drugs

There are no approved immune-booster or stem-cell drugs that treat this congenital triad. Using “stem-cell drugs” for this purpose would be unproven and potentially unsafe, so I cannot recommend them. Instead, here are evidence-based biologic/advanced options specialists sometimes use for the ocular surface, strictly under medical supervision:

1. Autologous serum eye drops (ASED).
   Dose: Specialist-prepared, multiple daily instillations. Function: Supplies growth factors/vitamins close to natural tears. Mechanism: Promotes corneal epithelial healing in severe dryness/exposure.

2. Platelet-rich plasma (PRP) eye drops.
   Function: High platelet growth factors support epithelial repair. Mechanism: Delivers EGF/PDGF/TGF-β to the ocular surface.

3. Cenegermin (recombinant human nerve growth factor) for neurotrophic keratitis (selected cases).
   Dose: 6×/day for 8 weeks (specialist indication). Function: Restores corneal nerve/epithelium health. Mechanism: TrkA/p75NTR signaling to promote corneal healing. Note: Not a routine therapy for all; used when criteria are met.

4. Topical cyclosporine/lifitegrast (listed above) as immunomodulators for chronic surface inflammation.
   Function: Improves tear function and reduces T-cell–mediated inflammation.

5. Amniotic membrane (suture or self-retaining device)—technically a surgical biologic, not a “drug.”
   Function: Protects and promotes corneal epithelialization. Mechanism: Anti-inflammatory/anti-fibrotic matrix.

6. Temporary botulinum-induced ptosis or tarsorrhaphy to biologically reduce exposure while healing—again procedural, not a systemic “immune booster,” but an effective regenerative environment for the cornea.

---

Surgeries

1. Primary eyelid coloboma repair (early).
   Procedure: Precise edge freshening and Z-plasty/W-plasty or direct closure; grafts if large.
   Why: Protects the cornea, restores lid margin and lashes for blinking and tear spread. NCBI

2. Temporary tarsorrhaphy (partial eyelid sewing) when needed.
   Procedure: Partially closes lids for weeks.
   Why: Short-term exposure protection before/after definitive repair.

3. Medial canthoplasty / telecanthus correction.
   Procedure: Repositioning of medial canthal tendon (e.g., trans-nasal fixation).
   Why: Narrows inner eye corner distance for function and appearance.

4. Nasal alar reconstruction.
   Procedure: Strengthening alar rims with septal/ear cartilage grafts; columellar and tip support; alar base positioning; external splints.
   Why: Prevents nostril collapse, improves airflow, and normalizes contour. BioMed Central

5. Staged rhinoplasty in later childhood/adolescence.
   Procedure: Growth-aware staged tip/alar/bridge refinement.
   Why: Achieves durable function and aesthetics once facial growth allows definitive shaping. BioMed Central

---

Prevention & protection tips

1. Early eye protection (lubricants, shields) to prevent corneal injury. NCBI

2. Keep follow-ups with ophthalmology and craniofacial teams.

3. Avoid eye rubbing and windy/dusty air; use humidifiers.

4. Use sun/UV protection to protect scars and reduce irritation.

5. Hand hygiene to reduce eye/skin infections.

6. Balanced nutrition (protein, vitamins A/C, zinc) for healing.

7. Prompt care for any eye redness, pain, or discharge.

8. Protective eyewear during play/sports.

9. Family genetic counseling if a FREM1-spectrum diagnosis is confirmed. MedlinePlus

10. Pre-op dental/respiratory hygiene to lower surgical infection risk.

---

When to see doctors (red flags)

• Any newborn with an eyelid gap (coloboma) or abnormal nostril rims—urgent ophthalmology visit.

• Eye pain, light sensitivity, redness, tearing, or vision blur—possible corneal exposure or ulcer (urgent). NCBI

• Noisy/effortful breathing through the nose, recurrent crusting/bleeding.

• Feeding difficulties, poor weight gain, or choking in infants.

• Social/learning concerns tied to vision or appearance—ask for supports early.

---

Foods to favor / to limit

Eat more of:

1. Lean proteins (fish, eggs, legumes) for tissue repair.

2. Colorful vegetables (vitamin A precursors in carrots, pumpkin).

3. Citrus and berries (vitamin C).

4. Whole grains (B-vitamins).

5. Nuts/seeds (healthy fats, zinc, selenium).

6. Dairy/fortified alternatives (vitamin D, protein).

7. Olive oil/avocado (anti-inflammatory fats).

8. Hydration (plain water).

9. Omega-3 sources (fatty fish; flax/chia if needed).

10. Yogurt/fermented foods (gut support during antibiotics).

Limit/avoid:

1. Very spicy/irritating foods right after nasal surgery.

2. Hard, sharp snacks that may bump early nasal repairs.

3. Excess sugar (inflammation).

4. Highly salty foods (dryness).

5. Alcohol (teens/adults)—impairs wound healing.

6. Smoking/vape exposure (household)—delays healing.

7. Unnecessary supplements beyond RDA without guidance.

8. Herbal anticoagulants (e.g., high-dose ginkgo) before surgery.

9. Very hot beverages immediately post-op (bleeding risk).

10. Allergens that trigger eye rubbing.

---

Frequently Asked Questions

1. Is this the same as frontonasal dysplasia or MOTA?
   Not exactly. Your phrase is a rare descriptive triad with minimal modern case reports; many clinicians today would evaluate it under the frontonasal/FREM1-related spectrum (such as MOTA) because the features overlap and the work-up/treatment plans are similar. Genetic Diseases Center+1

2. Is it inherited?
   The classic triad itself has too few cases to be sure. FREM1-related conditions such as MOTA are usually autosomal recessive, so genetic counseling is helpful. MedlinePlus

3. What is the main danger early on?
   Corneal exposure from the eyelid gap, which can scar vision if not protected quickly. NCBI

4. Can medicine fix the anatomy?
   No. Medicines protect and support; surgery corrects lids/nose spacing and structure.

5. When is surgery done?
   Eyelid protection happens early (even urgently). Definitive eyelid repair is often done in infancy/early childhood; nasal/telecanthus corrections are staged with growth.

6. Will my child see normally?
   If the cornea is protected and amblyopia is prevented/treated, many children can achieve good vision; early care is key. NCBI

7. Are stem-cell drugs a treatment?
   No approved stem-cell drugs treat this condition. Some biologic surface therapies (e.g., autologous serum drops) can aid healing in selected eye problems under specialist care.

8. Is nasal breathing affected?
   If alar rims are weak/collapsible, breathing can be noisier—reconstruction and stenting usually help.

9. How many surgeries are needed?
   Often more than one, planned with growth, aiming for both protection and appearance.

10. Will scars be obvious?
    Modern techniques place incisions in natural lines and use scar care to optimize appearance.

11. Does this affect learning or lifespan?
    Most FREM1-related patients have normal intelligence and life expectancy when treated; eye protection and social support matter. MedlinePlus

12. Should we do genetic testing?
    If features suggest FREM1-spectrum or frontonasal dysplasia, clinicians may order FREM1 and related panels to guide counseling. BioMed Central

13. Can glasses or contacts help?
    Yes—refractive correction and scleral/bandage lenses can protect and improve vision when appropriate.

14. What team do we need?
    Pediatric ophthalmology, craniofacial/plastic surgery, ENT, genetics, and speech/feeding specialists.

15. Where can I read more?
    See GARD on the exact triad name, MedlinePlus Genetics on MOTA/FREM1, StatPearls on eyelid coloboma care, and recent FREM1 reviews/case series. BioMed Central+3Genetic Diseases Center+3MedlinePlus+3

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 11, 2025.